What's Happening?
The National Institute of Animal Biotechnology (NIAB) in Hyderabad is inviting applications for specialized research and technical positions. This recruitment drive is part of a high-impact project led by Dr. Nirmalya Ganguli, focusing on developing an engineered
mammary epithelial cell-based bioreactor for producing human lactoferrin to treat iron deficiency anemia. The project aims to revolutionize therapeutic protein production using engineered mammalian cells as high-efficiency bioreactors. Positions available include Project Research Scientist I and Project Technical Support II, offering competitive remuneration and requiring specific educational and professional qualifications. The initiative is part of NIAB's mission to bridge the gap between basic research and biomanufacturing, contributing to cost-effective therapeutic solutions.
Why It's Important?
This recruitment is significant as it supports the development of innovative therapeutic solutions for iron deficiency anemia, a prevalent health issue. By focusing on biomanufacturing and cell engineering, NIAB aims to enhance the production of human lactoferrin, potentially reducing treatment costs and improving accessibility. The project also provides professionals in the life sciences sector with opportunities to work with cutting-edge technology and infrastructure, fostering career advancement and contributing to the national mission of developing cost-effective therapeutic proteins. This initiative could have a substantial impact on the biotechnology industry, promoting advancements in therapeutic protein production and application.
What's Next?
Interested candidates must submit their applications by March 13, 2026. Successful applicants will participate in an online walk-in interview process. The project is expected to advance through various stages of research and development, with potential collaborations and partnerships in the biotechnology sector. As the project progresses, it may attract further investment and interest from both public and private sectors, potentially leading to broader applications of the developed technologies in other therapeutic areas.
